<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated expression of the human ecotropic virus integration site-1 (EVI1) gene in patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) using the reverse transcriptase-polymerase chain reaction (RT-PCR) method </plain></SENT>
<SENT sid="1" pm="."><plain>The EVI1 transcripts were detected in 5 (10.0%) of 50 patients with de novo <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), including two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients with trilineage <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, and in 8 (34.8%) of 23 patients with post-<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (post-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>EVI1 expression was also detected in 6 (35.3%) of 17 MDS patients and three of six patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) in myelomegakaryoblast crisis </plain></SENT>
<SENT sid="3" pm="."><plain>No EVI1 transcripts were detected in patients with <z:hpo ids='HP_0006721'>acute lymphoid leukemia</z:hpo> (n = 15) or <z:mp ids='MP_0005481'>CML</z:mp> in lymphoid <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> (n = 4) </plain></SENT>
<SENT sid="4" pm="."><plain>Chromosomal abnormalities at the 3q26 region, where the EVI1 gene is located, were found in one patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and two patients with <z:mp ids='MP_0005481'>CML</z:mp> myelomegakaryoblast crisis who had EVI1 expression </plain></SENT>
<SENT sid="5" pm="."><plain>Our results showed that EVI1 expression was frequent in patients with post-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with trilineage <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, regardless of the presence or absence of 3q26 abnormalities </plain></SENT>
<SENT sid="6" pm="."><plain>EVI1 expression was accompanied by expression of GATA-1 and GATA-2, and often by stem cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (SCL) gene expression </plain></SENT>
<SENT sid="7" pm="."><plain>In patients with post-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, EVI1 expression was not always associated with a 3q26 abnormality, whereas EVI1 expression in <z:mp ids='MP_0005481'>CML</z:mp> myelomegakaryoblast crisis was often linked to a 3q26 abnormality </plain></SENT>
<SENT sid="8" pm="."><plain>Our results suggest that the leukemogenic role of EVI1 expression may differ between post-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:hpo ids='HP_0001909'>leukemia</z:hpo>, with EVI1 expression associated with a 3q26 abnormality </plain></SENT>
</text></document>